Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells

Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients

(2013) M. Fiegl et al.   ANNALS OF HEMATOLOGY

Complement factor H-derived short consensus repeat 18-20 enhanced complement-dependent cytotoxicity of ofatumumab on chronic lymphocytic leukemia cells

(2013) S. Horl et al.   HAEMATOLOGICA

The mechanism of anti-CD20–mediated B cell depletion revealed by intravital imaging

(2013) Fabricio Montalvao et al.   JOURNAL OF CLINICAL INVESTIGATION

Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity

(2013) S Hörl et al.   LEUKEMIA

Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab

(2013) Srinivas Mamidi et al.   Molecular Oncology

Antibody Therapeutics in Cancer

(2013) M. X. Sliwkowski et al.   SCIENCE

Boosting antibody therapy with complement

(2012) P. Boross et al.   BLOOD

A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer

(2012) M. Elvington et al.   BLOOD

Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy

(2012) S Bellone et al.   BRITISH JOURNAL OF CANCER

Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy

(2012) L. Bologna et al.   JOURNAL OF IMMUNOLOGY

Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement

(2012) Nisar A. Baig et al.   LEUKEMIA & LYMPHOMA

Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis

(2011) W. Hu et al.   CANCER RESEARCH

rILYd4, a Human CD59 Inhibitor, Enhances Complement-Dependent Cytotoxicity of Ofatumumab against Rituximab-Resistant B-cell Lymphoma Cells and Chronic Lymphocytic Leukemia

(2011) X. Ge et al.   CLINICAL CANCER RESEARCH

Inhibition of Membrane Complement Inhibitor Expression (CD46, CD55, CD59) by siRNA Sensitizes Tumor Cells to Complement Attack In Vitro

(2010) N. Geis et al.   CURRENT CANCER DRUG TARGETS

Complement: a key system for immune surveillance and homeostasis

(2010) Daniel Ricklin et al.   NATURE IMMUNOLOGY

Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX

(2009) A. W. Pawluczkowycz et al.   JOURNAL OF IMMUNOLOGY

Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development

(2009) Dana Gancz et al.   MOLECULAR IMMUNOLOGY

Modulation of the antitumor immune response by complement

(2008) Maciej M Markiewski et al.   NATURE IMMUNOLOGY

Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

(2008) Bruce D. Cheson et al.   NEW ENGLAND JOURNAL OF MEDICINE